← Leaderboards
Deborah Bunin
Sri International
$11,920,896
Attributed
$11,920,896
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $3.7M · FY2021–25$5M$3.8M$2.5M$1.3M$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$11,920,896 · 2
By mechanism
N01$11,920,896 · 2
Top collaborators
No co-investigators on record.
Most similar at Sri International
Same institution · by research overlap
- Toufan Parman$25,866,968
- Debra Burnin$9,670,591
- Leyi Gong$9,484,648
- Kathryn Baughman$29,412,662
- Mary Tanga$2,666,887
Others in their field
Other Emerging Leaders on “Design”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- John E West · University Of Texas At Austin$113,883,001
- Peter K Fritschel · California Institute Of Technology$78,820,000
- Kevin Urdahl · Seattle Children'S Hospital$72,239,698
- Marlene Ann Cooper · Harvard University D/B/A Harvard School Of Public Health$71,439,892
Research focus
DesignPre-ClinicalContraceptive AgentsBiological TestingEvaluationDrug FormulationsIn VivoResearch PersonnelInvestigational New Drug ApplicationClinical TrialsPharmaceutical PreparationsIn VitroStability TestingProduct DevelopmentResearch Clinical TestingToxic EffectPlasmaPlayContraceptive DevicesAnimalsOvulationPharmacokinetics And PharmacodynamicsClinical LotMission
Grant awards (16)
NICHD: R&D: PRECLINICAL SAFETY AND TOXICOLOGY STUDIES FOR REGULATORY REQUIREMENTS: NON-SEVERABLE$1,497,846
N01 · FY2025 · HD · contact PI
NICHD: R&D: ESSENTIAL STUDIES AND MANUFACTURE FOR CURRENT PRODUCTS IN ONGOING CLINICAL DEVELOPMENT: NON-SEVERABLE$1,249,426
N01 · FY2025 · HD · contact PI
GLP Toxicology Study for Adjuvanted HIV-1 Immunogen Vaccine Candidates$714,077
N01 · FY2025 · AI · contact PI
BIOLOGICAL TESTING FACILITY - CONTRACEPTIVE TARGET DATABASE AND APPLICATION$166,967
N01 · FY2025 · HD · contact PI
NICHD: R&D: ANDROGENIC, ANABOLIC, AND PRECLINICAL SAFETY STUDIES: NON-SEVERABLE$49,150
N01 · FY2025 · HD · contact PI
NICHD: R&D: BIOLOGICAL TESTING FACILITY - DRUG PRODUCT MANUFACTURE OF ONGOING CLINICAL DEVELOPMENT: NON-SEVERABLE$49,149
N01 · FY2025 · HD · contact PI
BIOLOGICAL TESTING FACILITY - DISCOVERY, CLINICAL FORMULATION, AND MANUFACTURE OF CONTRACEPTIVES$1,479,511
N01 · FY2024 · HD · contact PI
BIOLOGICAL TESTING FACILITY - CONTRACEPTIVE TARGET DATABASE AND APPLICATION$178,024
N01 · FY2024 · HD · contact PI
BIOLOGICAL TESTING FACILITY (BTF) - DEVELOPMENT OF CONTRACEPTIVE PRODUCTS INTENDED FOR NON-SYSTEMIC DELIVERY$1,372,326
N01 · FY2023 · HD · contact PI
BIOLOGICAL TESTING FACILITY - DISCOVERY, CLINICAL FORMULATION, AND MANUFACTURE OF CONTRACEPTIVES$1,098,133
N01 · FY2023 · HD · contact PI
BIOLOGICAL TESTING FACILITY - CONTRACEPTIVE TARGET APPLICATION$199,669
N01 · FY2023 · HD · contact PI
BIOLOGICAL TESTING FACILITY - RESEARCH, OPTIMIZATION, AND DEVELOPMENT OF CONTRACEPTIVE$1,453,074
N01 · FY2022 · HD · contact PI
BIOLOGICAL TESTING FACILITY - CONTRACEPTIVE TARGET APPLICATION$228,992
N01 · FY2022 · HD · contact PI
BIOLOGICAL TESTING FACILITY, TASK ORDER 7: CONTRACEPTIVE PRECLINICAL RESEARCH AND DEVELOPMENT$1,087,798
N01 · FY2021 · HD · contact PI
BIOLOGICAL TESTING FACILITY, TASK ORDER 6: CONTRACEPTIVE FORMULATION DEVELOPMENT AND MANUFACTURING$971,034
N01 · FY2021 · HD · contact PI
BIOLOGICAL TESTING FACILITY â "QUANTITATIVE STRUCTURE ACTIVITY RELATIONSHIP"$125,720
N01 · FY2021 · HD · contact PI